Assessment of risks of pulmonary infection during 12 months following immunosuppressive treatment for active connective tissue diseases: A large-scale prospective cohort study

Hayato Yamazaki, Ryoko Sakai, Ryuji Koike, Yasunari Miyazaki, Michi Tanaka, Toshihiro Nanki, Kaori Watanabe, Shinsuke Yasuda, Takashi Kurita, Yuko Kaneko, Yoshiya Tanaka, Yasuhiko Nishioka, Yoshinari Takasaki, Kenji Nagasaka, Hayato Nagasawa, Shigeto Tohma, Makoto Dohi, Takahiko Sugihara, Haruhito Sugiyama, Yasushi KawaguchiNaohiko Inase, Sae Ochi, Hiroyuki Hagiyama, Hitoshi Kohsaka, Nobuyuki Miyasaka, Masayoshi Harigai

研究成果: Article査読

8 被引用数 (Scopus)

抄録

Objective. Pulmonary infections (PI) are leading causes of death in patients with connective tissue diseases (CTD). The PREVENT study (Pulmonary infections in patients REceiving immunosuppressiVE treatmeNT for CTD) assessed risk of PI in patients with active CTD in the contemporary era of advanced immunosuppressive therapy. Methods. In patients who started corticosteroids (n = 763), conventional immunosuppressants or biologics for active CTD were enrolled. Clinical and laboratory data, usage of drugs, and occurrence of PI were collected for 12 months. Baseline risk factors were investigated using Cox regression analysis. A nested case-control (NCC) study was performed with 1:2 matched case-control pairs to assess the risk for each drug category. Results. During the observation period, 32 patients died (4.2%) and 66 patients were lost to followup (8.6%). Patients with PI (n = 61, 8%) had a significantly worse accumulated survival rate than patients without (p ≤ 0.01). Cox hazard regression analysis using baseline data showed that these factors were significantly associated with PI: age > 65 years (HR 3.87, 95% CI 2.22-6.74), > 20 pack-years of smoking (2.63, 1.37-5.04), higher serum creatinine level (1.21, 1.05-1.41 per 1.0 mg/dl increase), and maximum prednisolone (PSL) dose during the first 2 weeks of treatment (2.81, 1.35-5.86 per 1.0 mg/kg/day increase). Logistic regression analysis by an NCC study revealed that maximum PSL dose within 14 days before PI (OR 4.82, 95% CI 1.36-17.01 per 1.0 mg/dl increase; 2.57, 1.28-5.16 if > 0.5 mg/kg/day) was significantly associated with the events, while other immunosuppressants were not. Conclusion. Physicians should be aware of the higher risks for corticosteroids of PI than other immunosuppressants and assess these risk factors before immunosuppressive treatment, to prevent PI.

本文言語English
ページ(範囲)614-622
ページ数9
ジャーナルJournal of Rheumatology
42
4
DOI
出版ステータスPublished - 2015 4 1

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

フィンガープリント 「Assessment of risks of pulmonary infection during 12 months following immunosuppressive treatment for active connective tissue diseases: A large-scale prospective cohort study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル